XENE Insider Trading
Insider Ownership Percentage: 5.52%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,535,891.27
Xenon Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Xenon Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Xenon Pharmaceuticals Share Price & Price History
Current Price: $34.26
Price Change: ▼ Price Decrease of -0.2 (-0.58%)
As of 03/28/2025 05:00 PM ET
Xenon Pharmaceuticals Insider Trading History
Xenon Pharmaceuticals Institutional Trading History
Data available starting January 2016
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Read More on Xenon Pharmaceuticals
Today's Range
Now: $34.26
52 Week Range
Now: $34.26
Volume
288,804 shs
Average Volume
394,242 shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.26
Who are the company insiders with the largest holdings of Xenon Pharmaceuticals?
Who are the major institutional investors of Xenon Pharmaceuticals?
Which major investors are selling Xenon Pharmaceuticals stock?
During the last quarter, XENE stock was sold by these institutional investors:
- Capital World Investors
- Avidity Partners Management LP
- Marshall Wace LLP
- Adage Capital Partners GP L.L.C.
- ExodusPoint Capital Management LP
- Federated Hermes Inc.
- Ensign Peak Advisors Inc
- D. E. Shaw & Co. Inc.
During the previous year, company insiders that have sold Xenon Pharmaceuticals company stock include:
- Ian Mortimer (CEO)
- Dawn Svoronos (Director)
- Gary Patou (Director)
Learn More investors selling Xenon Pharmaceuticals stock.
Which major investors are buying Xenon Pharmaceuticals stock?
Within the last quarter, XENE stock was bought by institutional investors including:
- FMR LLC
- Boxer Capital Management LLC
- JPMorgan Chase & Co.
- Stempoint Capital LP
- Janus Henderson Group PLC
- Polar Capital Holdings Plc
- Jennison Associates LLC
- Braidwell LP